Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Adjuvant Palbociclib for HR+ Breast Cancer
The five-year follow-up of the PALLAS trial did not show improved invasive disease-free survival with the addition of palbociclib to endocrine therapy in patients with early-stage
New Reference: Abemaciclib for Adjuvant Breast Cancer
Adjuvant abemaciclib plus endocrine therapy (ET) showed a significant but small improvement in overall survival compared to ET alone in HR-positive, HER2-negative, high-risk early
New Reference: Alectinib for ALK-Positive Advanced NSCLC
The ALEX study demonstrated that alectinib numerically prolongs overall survival compared to crizotinib in patients with untreated ALK-positive non-small cell lung cancer. Alectini
New Drug: Imlunestrant for ESR1-Mutated Advanced Breast Cancer
In patients with ESR1 mutations, imlunestrant significantly improved progression-free survival compared to standard therapy. Imlunestrant–abemaciclib further improved progression
New Indication: Amivantamab-Lazertinib for First Line Advanced EGFR-Mutated NSCLC
The MARIPOSA trial demonstrated that amivantamab-lazertinib significantly improved overall survival compared to osimertinib in EGFR-mutated advanced NSCLC in 1st line setting, with
New Protocol: Belantamab Mafodotin with Bortezomib/Dexamethasone for R/R Myeloma
Global, randomised, open-label, phase 3 trial [DREAMM-7] Relapsed or refractory multiple myeloma after at least one line of therapy Belantamab-Bortezomib-dexamethasone (BVd) (n=243
New Drug: Telisotuzumab vedotin for cMET Amplified NSCLC
Phase 2, non-randomized, multicenter study (LUMINOSITY) Previously treated c-Met overexpressing NSQ EGFR wildtype advanced NSCLC (≤2 prior lines, ≤1 chemo) Telisotuzumab vedoti
New Drug: Penpulimab with Platinum – Gemcitabine in Advanced Nasopharyngeal Carcinoma
Global, multicenter, randomized, double-blind, phase 3 trial (AK105-304) Previously untreated recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) Penpulimab + gemcitabine/ci
New REference: Talazoparib and Enzalutamide for HRR-Deficient Prostate Cancer
Randomised, placebo-controlled, phase 3 trial [TALAPRO-2] Metastatic castration-resistant prostate cancer with HRR-deficiency Talazoparib+enzalutamide (n=200) vs enzalutamide+plac
